NCT04672135View on ClinicalTrials.gov

A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

April 26, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

REM0046127

Oral solution: 100 mg/mL REM0046127

DRUG

Placebo

Oral solution with 0 mg/mL REM0046127

Trial Locations (1)

1090

Medical University Vienna, Department of Clinical Pharmacology, Vienna

Sponsors

Lead Sponsor

reMYND
All Listed Sponsors
collaborator

NeuroScios GmbH

UNKNOWN

lead

reMYND

INDUSTRY